Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 4Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Genitourinary 6

Conditions

Breast Neoplasms 3092Neoplasms 2436Carcinoma, Non-Small-Cell Lung 1863Prostatic Neoplasms 1617Colorectal Neoplasms 1422Lung Neoplasms 1292Multiple Myeloma 927Neoplasm Metastasis 919Leukemia, Myeloid, Acute 874Pancreatic Neoplasms 847Ovarian Neoplasms 799Melanoma 783Carcinoma, Hepatocellular 736Stomach Neoplasms 639Brain Neoplasms 635Recurrence 633Squamous Cell Carcinoma of Head and Neck 630Head and Neck Neoplasms 609Glioblastoma 566Lymphoma 539Uterine Cervical Neoplasms 537Triple Negative Breast Neoplasms 504Precursor Cell Lymphoblastic Leukemia-Lymphoma 499Carcinoma, Renal Cell 497Hematologic Neoplasms 462Urinary Bladder Neoplasms 459Endometrial Neoplasms 459Colonic Neoplasms 441Lymphoma, Non-Hodgkin 435Sarcoma 434

Interventions

Androgen Antagonists 3darolutamide 2Docetaxel 2relugolix 1niraparib 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Metastatic Hormone-sensitive Prostate Cancer (mHSPC) × 1 year × Clear all
NCT07395804 2026-05-29

23146

Bayer

Recruiting
500 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06661122 2026-05-19

HAYATE

Bayer

Recruiting
100 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07241416 2026-05-11

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
206 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06010914 2026-04-15

DADOX

Bayer

Active not recruiting
100 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06392841 2026-04-08

HARMONY

Hoosier Cancer Research Network

Phase 2 Withdrawn
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07216248 2025-10-29

OPTIMAS

University of Utah

Phase 2 Recruiting
160 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡